Status:
COMPLETED
Improving Vaccination in Older Adults by Inducing Autophagy With Spermidine
Lead Sponsor:
University of Oxford
Conditions:
COVID-19
Vaccine Reaction
Eligibility:
All Genders
65-90 years
Phase:
NA
Brief Summary
Easing the morbidity and economic burden of age-related diseases is one of the major medical challenges. One of the key obstacles to healthy ageing is immune senescence, including the failure of lymph...
Detailed Description
The outbreak of SARS-CoV-2 and coronavirus disease (COVID-19) has caused a great threat to global public health with the majority of deaths occurring in older adults. The development of effective trea...
Eligibility Criteria
Inclusion
- Participants must be 65 years old or more and must have the capacity to provide written consent after discussing the participant information sheet with a member of the clinical study team. Participants must have received 2 doses of the COVID vaccine and a booster dose.
Exclusion
- Participants who are acutely unwell.
- Participants who have had a clear clinical history of COVID symptoms or a previous positive COVID PCR( polymerase chain reaction) swab or antibody test
- Participants who cannot provide informed written consent
- Participants who use systemic steroids for more than one week e.g prednisolone \>0.5mg/kg/day in the three months prior to first study intervention
- Chronic administration (≥14 days in total) of immunosuppressants or other immune modifying drugs in the 3 months prior to first study intervention
- Receipt of blood, blood products and/or plasma derivatives or any immunoglobulin preparation in the three months prior to first study intervention
- Participants who have been diagnosed with medical conditions that can suppress the immune system or diabetes
- Participants with previous allergy to or constituent parts of Spermidine supplements or who have gluten intolerance
- Participants already taking Spermidine supplements at the time of recruitment or for 6 months prior to recruitment to the study
- Participants that are in custody
- Participants that do not live in the UK
- Participants that are pregnant
- Participants who are shielding
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05421546
Start Date
August 1 2022
End Date
December 2 2023
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oxford
Oxford, United Kingdom